To Treat or Not to Treat: a Comparative Effectiveness Analysis of Oral Anticoagulant Outcomes Among U.S. Nursing Home Residents with Atrial Fibrillation

Overview

Journal BMC Geriatr

Publisher Biomed Central

Specialty Geriatrics

Date 2024 Jul 19

PMID 39030486

Authors

Qiaoxi Chen

Jonggyu Baek

Robert Goldberg

Jennifer Tjia

Kate Lapane

Matthew Alcusky

Affiliations

Soon will be listed here.

Abstract

Background: Nursing home residents with atrial fibrillation are at high risk for ischemic stroke, but most are not treated with anticoagulants. This study compared the effectiveness and safety between oral anticoagulant (OAC) users and non-users.

Methods: We conducted a new-user retrospective cohort study by using Minimum Data Set 3.0 assessments linked with Medicare claims. The participants were Medicare fee-for-service beneficiaries with atrial fibrillation residing in US nursing homes between 2011 and 2016, aged ≥ 65 years. The primary outcomes were occurrence of an ischemic stroke or systemic embolism (effectiveness), occurrence of intracranial or extracranial bleeding (safety) and net clinical outcome (effectiveness or safety outcomes). Secondary outcomes included total mortality and a net clinical and mortality outcome. Cox proportional hazards and Fine and Grey models estimated multivariable adjusted hazard ratios (aHRs) and sub-distribution hazard ratios (sHRs).

Results: Outcome rates were low (effectiveness: OAC: 0.86; non-users: 1.73; safety: OAC: 2.26; non-users: 1.75 (per 100 person-years)). OAC use was associated with a lower rate of the effectiveness outcome (sHR: 0.69; 95% Confidence Interval (CI): 0.61-0.77), higher rates of the safety (sHR: 1.70; 95% CI: 1.58-1.84) and net clinical outcomes (sHR: 1.20; 95% CI: 1.13-1.28) lower rate of all-cause mortality outcome (sHR: 0.60; 95% CI: 0.59-0.61), and lower rate of the net clinical and mortality outcome (sHR: 0.60; 95% CI: 0.59-0.61). Warfarin users, but not DOAC users, had a higher rate of the net clinical outcome versus OAC non-users.

Conclusions: Our results support the benefits of treatment with OACs to prevent ischemic strokes and increase longevity, while highlighting the need to weigh apparent benefits against elevated risk for bleeding. Results were consistent with net favorability of DOACs versus warfarin.

References

Mant J, Hobbs F, Fletcher K, Roalfe A, Fitzmaurice D, Lip G . Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586):493-503. DOI: 10.1016/S0140-6736(07)61233-1. View

Alcusky M, McManus D, Hume A, Fisher M, Tjia J, Lapane K . Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016. J Am Heart Assoc. 2019; 8(9):e012023. PMC: 6512099. DOI: 10.1161/JAHA.119.012023. View

Graham D, Reichman M, Wernecke M, Zhang R, Southworth M, Levenson M . Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2014; 131(2):157-64. DOI: 10.1161/CIRCULATIONAHA.114.012061. View

Connolly S, Eikelboom J, Joyner C, Diener H, Hart R, Golitsyn S . Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9):806-17. DOI: 10.1056/NEJMoa1007432. View

Almutairi A, Zhou L, Gellad W, Lee J, Slack M, Martin J . Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Clin Ther. 2017; 39(7):1456-1478.e36. DOI: 10.1016/j.clinthera.2017.05.358. View

Alcusky M, Tjia J, McManus D, Hume A, Fisher M, Lapane K . Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents. J Gen Intern Med. 2020; 35(8):2329-2337. PMC: 7403286. DOI: 10.1007/s11606-020-05777-3. View

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

Fang M, Go A, Chang Y, Borowsky L, Pomernacki N, Udaltsova N . A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011; 58(4):395-401. PMC: 3175766. DOI: 10.1016/j.jacc.2011.03.031. View

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

10.

Kumbhani D, Cannon C, Beavers C, Bhatt D, Cuker A, Gluckman T . 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A.... J Am Coll Cardiol. 2020; 77(5):629-658. DOI: 10.1016/j.jacc.2020.09.011. View

11.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

12.

Wu H, Chang S, Lee T, Tu H, Liu C, Chang T . Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants-A nationwide cohort study. Front Cardiovasc Med. 2022; 9:969259. PMC: 9393418. DOI: 10.3389/fcvm.2022.969259. View

13.

Rash A, Downes T, Portner R, Yeo W, Morgan N, Channer K . A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2006; 36(2):151-6. DOI: 10.1093/ageing/afl129. View

14.

Bhagavathula A, Vidyasaga K, Gebreyohannes E, Tesfaye W . Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants. Ann Pharmacother. 2021; 56(7):820-830. DOI: 10.1177/10600280211049727. View

15.

Petri H, Urquhart J . Channeling bias in the interpretation of drug effects. Stat Med. 1991; 10(4):577-81. DOI: 10.1002/sim.4780100409. View

16.

Wheelock K, Ross J, Murugiah K, Lin Z, Krumholz H, Khera R . Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. JAMA Netw Open. 2021; 4(12):e2137288. PMC: 8649845. DOI: 10.1001/jamanetworkopen.2021.37288. View

17.

Coleman C, Peacock W, Bunz T, Alberts M . Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017; 48(8):2142-2149. DOI: 10.1161/STROKEAHA.117.017474. View

18.

Kakkar A, Mueller I, Bassand J, Fitzmaurice D, Goldhaber S, Goto S . International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2011; 163(1):13-19.e1. DOI: 10.1016/j.ahj.2011.09.011. View

19.

Shah S, Singer D, Fang M, Reynolds K, Go A, Eckman M . Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019; 12(11):e006212. PMC: 7117790. DOI: 10.1161/CIRCOUTCOMES.119.006212. View

20.

Dube C, Mack D, Hunnicutt J, Lapane K . Cognitive Impairment and Pain Among Nursing Home Residents With Cancer. J Pain Symptom Manage. 2018; 55(6):1509-1518. PMC: 5951760. DOI: 10.1016/j.jpainsymman.2018.02.012. View